Recombinant COVID-19 Vaccine (CHO Cell) (Zifivax) Approved for Heterologous Booster in Indonesia

On January 10, 2022, National Agency of Drug and Food Control of Indonesia (BPOM) held a press conference to announce that our Recombinant COVID-19 Vaccine (CHO cell) (“Zifivax”) was approved as a heterologous booster for inactivated COVID-19 vaccines. 
Penny K.Lukito, head of BPOM, noted that one dose of Zifivax, administered as heterologous booster six months after prime immunization of two doses of inactivated vaccines, could increase neutralizing antibody levels by about 30 times.

References: Badan POM Resmikan Vaksin COVID-19 Dosis Booster/Lanjutan di Indonesia (https://www.pom.go.id/new/view/more/pers/635/Badan-POM-Resmikan-Vaksin-COVID-19-Dosis-Booster-Lanjutan-di-Indonesia.html）

 About the Recombinant COVID-19 Vaccine (CHO Cell)

The Recombinant COVID-19 Vaccine (CHO Cell) is a recombinant protein subunit vaccine co-developed by IMCAS and Zhifei Longcom, the wholly-owned subsidiary of Zhifei. It is prepared by expressing pathogen antigen proteins in engineered cells by means of genetic engineering, and is with completely independent intellectual property rights. The vaccine was registered and marketed in Uzbekistan on March 1, 2021, becoming the first recombinant COVID-19 vaccine registered and marketed in the world. It was approved for emergency use in China and Indonesia on March 10, and October 7, 2021, respectively.

The results of the international Multi-Regional Phase III clinical trials showed that the vaccine had an efficacy of 81.43% against any severity of COVID-19. Preliminary genotyping results showed that the efficacy of the vaccine against Alpha and Delta variants were 92.68% and 81.38%, respectively.